33252-29-8

Basic information

• Product Name: 2-Chloro-6-cyanopyridine
• Synonyms: 6-Chloropyridine-2-carbonitrile 98%;6-Chloropyridine-2-carbonitrile, 98%+;6-CHLORO-2-CYANOPYRIDINE;6-CHLOROPYRIDINE-2-CARBONITRILE;6-CHLOROPICOLINONITRILE;2-CHLORO-6-CYANOPYRIDINE;2-Cyno-6-chloropyridine;P-1002-Chloro-6-Cyanopyridine
• CAS NO: 33252-29-8
• Molecular Formula: C₆H₃ClN₂
• Molecular Weight: 138.55
• EINECS: 251-429-7
• Product Categories: Pyridine series;Pyridines;Halides;Pyridine
• Mol File: 33252-29-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 85-89 °C
• Boiling Point: 245.3 °C at 760 mmHg
• Flash Point: 102.1 °C
• Appearance: off-white cryst
• Density: 1.33 g/cm³
• Vapor Pressure: 0.029mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -5.77±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-6-cyanopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-cyanopyridine(33252-29-8)
• EPA Substance Registry System: 2-Chloro-6-cyanopyridine(33252-29-8)

Safety Data

• Hazard Codes: Xn,T,Xi
• Statements: 22-37/38-41-36/37/38
• Safety Statements: 26-36/37/39-37
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 33252-29-8(Hazardous Substances Data)

Usage

Chemical Properties

Off-white Cryst

Uses

Substrate used in a Negishi coupling reaction with an arylzinc halide catalyzed by Pd-NHC (PEPPSI-Ipr, Catalog No. 668032).

InChI:InChI=1/C6H3ClN2/c7-6-3-1-2-5(4-8)9-6/h1-3H

Upstream product

• 2402-95-1 2-chloropyridine-N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 773837-37-9 sodium cyanide 
• 87512-29-6 2-chloro-6-(methylsulfonyl)pyridine 
• 20295-64-1 2-chloropyridine N-oxide hydrochloride 
• 104727-52-8 ethyl 6-chloropyridine-2-carboximidate 
• 143-33-9 sodium cyanide 
• 116570-79-7 N-methoxy-2-chloropyridinium methylsulfate 
• 100-70-9 2-Cyanopyridine 
• 2402-78-0 2,6-dichloropyridine 
• 109-09-1 2-chloropyridine 
• 87512-28-5 2-chloro-6-methylsulfinyl pyridine 
• 77145-64-3 2-chloro-6-methylsulphenylpyridine 

Downstream Products

• 205174-21-6 2-cyano-6-(2-methoxyphenyl)pyridine 
• 501378-42-3 6-(methylsulfanyl)pyridine-2-carbonitrile 
• 1012330-21-0 2-cyano-6-(2-(3-(biphenyl-4-yl)-1-(tert-butyldimethylsilyloxy)propyl)oxazol-5-yl)pyridine 
• 1012330-68-5 2-cyano-6-(2-(1-(tert-butyldimethylsilyloxy)-3-(4-(phenoxymethyl)phenyl)propyl)oxazol-5-yl)pyridine 
• 1135871-76-9 6-(3-acetyl-phenyl)-pyridine-2-carbonitrile 
• 120613-15-2 6-vinylpyridine-2-carbonitrile 
• 1184873-44-6 6-(4-acetylphenyl)pyridine-2-carbonitrile 
• 1374675-13-4 6-[(S)-3-((S)-2-chloro-4-hexahydro-pyrrolo[1,2-a]pyrazin-2-yl-benzenesulfonyl)-pyrrolidin-1-yl]-pyridine-2-carbonitrile 
• 1431558-41-6 C₁₈H₁₃ClN₄S 
• 185107-64-6 5,6-dichloropyridine-2-carbonitrile 
• 1702-18-7 3,6-dichloro-2-pyridinecarbonitrile 
• 501378-85-4 2-cyano-6-(2-phenethylthio)pyridine 
• 188637-75-4 (6-chloropyridin-2-yl)methylamine 
• 99902-95-1 6-(3,4-Dichloro-phenoxy)-pyridine-2-carbonitrile 

Relevant articles and documents

Structure-dependent regioselectivity of a roll-over cyclopalladation occuring at 2,2′-bipyridine-type ligands

In this work, different bipyridine-analogue ligands bearing a dimethylamino group in the meta-position of one of the heterocyclic rings were synthesized and reacted with palladium(II) acetate under identical conditions. Cyclometallated palladium(II) complexes with C,N- or C,N,N’-coordinating chelate ligands are formed which were characterized by elemental analysis, 1H and 13C NMR spectroscopy, and single crystal X-ray diffraction analysis. In the case of the mononuclear, C,N,N’-coordinated complex, which is formed by an attack of the palladium(II) site at of the N-methyl groups, the primarily coordinating acetato ligand is exchanged against a chlorido ligand, which is liberated from the solvent dichloromethane by a nucleophilic substitution reaction. In contrast, cyclometallation occurring at one of the six-membered heterocycles leads to dinuclear acetato-bridged palladium(II) complexes.

Preparation method of 2, 3-dichloro-6-cyanopyridine

The invention discloses a preparation method of 2, 3-dichloro-6-cyanopyridine, and the method comprises the following steps: by using a metal chloride salt as a catalyst and phosphorus halide as a cocatalyst, carrying out one-step liquid-phase chlorination reaction on raw materials 2-chloro-6-cyanopyridine and chlorine to obtain 2, 3-dichloro-6-cyanopyridine; wherein the metal chloride salt is selected from at least one of WCl6, MoCl5, FeCl3, AlCl3, CuCl2, ZnCl2, RuCl3, SnCl4 and SbCl5, and the cocatalyst is selected from at least one of phosphorus pentachloride, phosphorus trichloride, phosphorus pentabromide and phosphorus tribromide. The method is simple in reaction process, low in production cost and high in target product selectivity and yield, the yield is 90% or above by optimizingreaction conditions, and the method has a good industrial prospect.

1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF

This invention provides a compound represented by the formula (I) :wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.